

Specialty Guideline Management

Empliciti

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
|------------|--------------|
| Empliciti | elotuzumab |

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

- Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Compendial Uses²

Therapy for previously treated multiple myeloma for relapsed or progressive disease in combination with bortezomib and dexamethasone.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Multiple Myeloma¹⁻³

Authorization of 12 months may be granted for the treatment of previously treated multiple myeloma when any of the following criteria are met:

- The requested medication will be used in combination with lenalidomide and dexamethasone
- The requested medication will be used in combination with bortezomib and dexamethasone
- The requested medication will be used in combination with pomalidomide and dexamethasone in members who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Empliciti [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2022.
2. The NCCN Drugs & Biologics Compendium 2024 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed September 26, 2024.
3. The NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (Version 1.2025) 2024 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed September 26, 2024.